Opioid treatment programs, telemedicine and COVID-19: A scoping review-Reference-Cited by-同舟云学术

Opioid treatment programs, telemedicine and COVID-19: A scoping review

Published:2021-09-14 Issue:1 Volume:43 Page:539-546
ISSN:0889-7077
Container-title:Substance Abuse
language:en
Short-container-title:Substance Abuse

Author:

Chan Brian¹²^ORCID,Bougatsos Christina¹,Priest Kelsey C.³^ORCID,McCarty Dennis¹⁴^ORCID,Grusing Sara¹,Chou Roger¹

Affiliation:

1. Department of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA

2. Division of General Internal Medicine & Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA

3. OHSU School of Medicine, MD/PhD Program, Oregon Health & Science University, Portland, OR, USA

4. OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, OR, USA

Funder

Arnold Ventures

National Institute on Drug Abuse

Publisher

Informa UK Limited

Subject

Psychiatry and Mental health,Medicine (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/08897077.2021.1967836

Reference36 articles.

1. Substance Abuse and Mental Health Services Administration. Statutes, regulations, and guidelines. https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines. Accessed August 31, 2020.

2. Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States

3. The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations

4. Drug Enforcement Administration (DEA), Department of Justice. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. DEA and Department of Justice. Federal Register. 2009;74(64):15595–15625. https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr0930_2.htm

5. Substance Abuse and Mental Health Services Administration. FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed August 31 2020.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis;Journal of Substance Use and Addiction Treatment;2024-12

2. Digital health interventions to support women with opioid use disorder: A scoping review;Drug and Alcohol Dependence;2024-08

3. Considerations for Opioid Use Disorder Treatment From Policy Makers’ Experiences With COVID-19 Policy Flexibilities;Psychiatric Services;2024-06-05

4. Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland;Harm Reduction Journal;2024-05-08

5. Barriers to retention in medications for opioid use disorder treatment in real-world practice;Journal of Substance Use and Addiction Treatment;2024-05